CalciMedica reports Q3 net loss of $7.8 mln

Reuters

Nov 12

CalciMedica reports Q3 net loss of $7.8 mln

Overview

CalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-ago
Positive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026

Outlook

Company expects cash position to fund operations into 2H 2026
CalciMedica expects pivotal trial design for AP finalized in 1H 2026
Data from Phase 2 KOURAGE trial expected in 1H 2026

Result Drivers

COSTS - R&D costs rose to $3.9 mln from $3.6 mln, while G&A expenses dropped to $1.8 mln from $2.2 mln

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$7.80 mln
Q3 Basic EPS		-$0.52
Q3 Income From Operations		-$5.62 mln
Q3 Operating Expenses		$5.62 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CalciMedica Inc is $15.50, about 79.3% above its November 11 closing price of $3.21

Press Release: ID:nPn5W9Ry8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582637560"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582637560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582637560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582637560","market":"us","top_or_hot":-1,"title":"CalciMedica reports Q3 net loss of $7.8 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CalciMedica reports Q3 net loss of $7.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>CalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-ago</p></li><li><p>Positive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash position to fund operations into 2H 2026</p></li><li><p>CalciMedica expects pivotal trial design for AP finalized in 1H 2026</p></li><li><p>Data from Phase 2 KOURAGE trial expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COSTS - R&amp;D costs rose to $3.9 mln from $3.6 mln, while G&amp;A expenses dropped to $1.8 mln from $2.2 mln </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.80 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.52</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$5.62 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CalciMedica Inc is $15.50, about 79.3% above its November 11 closing price of $3.21</p></li></ul><p>Press Release: <span>ID:nPn5W9Ry8a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica reports Q3 net loss of $7.8 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica reports Q3 net loss of $7.8 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CalciMedica reports Q3 net loss of $7.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>CalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-ago</p></li><li><p>Positive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash position to fund operations into 2H 2026</p></li><li><p>CalciMedica expects pivotal trial design for AP finalized in 1H 2026</p></li><li><p>Data from Phase 2 KOURAGE trial expected in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COSTS - R&amp;D costs rose to $3.9 mln from $3.6 mln, while G&amp;A expenses dropped to $1.8 mln from $2.2 mln </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.80 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.52</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$5.62 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CalciMedica Inc is $15.50, about 79.3% above its November 11 closing price of $3.21</p></li></ul><p>Press Release: <span>ID:nPn5W9Ry8a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CALC","symbol_name":"CALCIMEDICA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0DA:1","article_id":"2582637560","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582637560","pubTimestamp":1762949753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CalciMedica reports Q3 net loss of $7.8 mlnOverviewCalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-agoPositive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CALC":"CALCIMEDICA","BK4007":"制药"},"translate_title":"CalciMedica报告第三季度净亏损780万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"CalciMedica reports Q3 net loss of $7.8 mlnOverviewCalciMedica reports Q3 net loss of $7.8 mln vs $5.6 mln year-agoPositive FDA discussions on pivotal trial for acute pancreatitis, design expected 1H 2026OutlookCompany expects cash position to fund operations into 2H 2026CalciMedica expects pivotal trial design for AP finalized in 1H 2026Data from Phase 2 KOURAGE trial expected in 1H 2026Result DriversCOSTS - R&D costs rose to $3.9 mln from $3.6 mln, while G&A expenses dropped to $1.8 mln from $2.2 mln Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$7.80 mlnQ3 Basic EPS-$0.52Q3 Income From Operations-$5.62 mlnQ3 Operating Expenses$5.62 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for CalciMedica Inc is $15.50, about 79.3% above its November 11 closing price of $3.21Press Release: ID:nPn5W9Ry8aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}